QURE News and Press, uniQure N.V. From 06/21/23

~ AMT-130 continues to be generally well-tolerated across both dose cohorts ~ ~ Patients treated with AMT-130 show preserved function compared to baseline and clinical benefits relative to natural history of the disease ~ ~ Neurofilament Light Chain (NfL) in cerebrospinal fluid ...

LEXINGTON, Mass. and AMSTERDAM, June 20, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced the achievement of a $100 million milestone associated with the first commercial s...

CSL Behring Announces the First Patient Has Received FDA-Approved HEMGENIX® (etranacogene dezaparvovec-drlb) for Hemophilia B PR Newswire HEMGENIX ® , the first and only FDA approved gene therapy for hemophilia B, has been proven to elevate and sustain factor IX ...

2023-05-22 17:38:02 ET Summary uniQure secured FDA approval late last year and EMA approval in Q1 2023 for its AMT-061 Hemophilia B treatment. This paves the way for its commercialization in the US and EU. It also has a healthy R&D pipeline, with its Huntington’s diseas...

2023-05-20 09:19:55 ET Summary uniQure's strong financial performance and remarkable revenue growth highlight the company's continued upward trajectory, making it a promising investment opportunity. Innovative gene therapies such as HEMGENIX for hemophilia B and AMT-130 for Huntin...

2023-05-15 08:26:38 ET Dutch biotech uniQure N.V. ( NASDAQ: QURE ) added ~7% pre-market Monday after announcing an agreement to sell a portion of royalty rights expected to receive from Australian drugmaker CSL Limited ( OTCQX:CSLLY ) in relation to the gene therapy Hemgenix...

~ uniQure to receive $375 million upfront cash payment ~ ~ Under the existing agreement with CSL Behring, uniQure retains the rights to future milestones totaling up to $1.5 billion and maintains an interest in HEMGENIX ® royalties ~ ~ Capped royalty financing provi...

2023-05-09 08:42:56 ET uniQure press release ( NASDAQ: QURE ): Q1 GAAP EPS of -$1.63 misses by $0.73 . Revenue of $5.33M (+197.8% Y/Y). As of March 31, 2023, the Company had cash and cash equivalents and investment securities of $315.3 million. The Company expe...

~ Clinical update from U.S. Phase I/II trial in Huntington’s disease expected in second quarter 2023 ~ ~ Continued progress towards initiating two new Phase I/II clinical studies for AMT-260 in refractory temporal lobe epilepsy and AMT-162 in SOD1-ALS ~ LEXINGTON, Mass and ...

LEXINGTON, Mass. and AMSTERDAM, May 02, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that 12 data presentations, including two oral presentations, will be deliver...